• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Spero Therapeutics Inc.

    2/14/24 4:25:21 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRO alert in real time by email
    SC 13G 1 d764526dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    (Amendment No. )

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

     

    SPERO THERAPEUTICS, INC.

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    84833T103

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

     

     


    CUSIP No. 84833T103    13G   

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Anson Funds Management LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Texas

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     4,297,599

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     4,297,599

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,297,599

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.1% **

    12  

     TYPE OF REPORTING PERSON*

     

     IA, PN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    2


    CUSIP No. 84833T103    13G   

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Anson Management GP LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Texas

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     4,297,599

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     4,297,599

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,297,599

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.1% **

    12  

     TYPE OF REPORTING PERSON*

     

     HC, OO

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    3


    CUSIP No. 84833T103    13G   

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Tony Moore

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States Citizen

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     4,297,599

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     4,297,599

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,297,599

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.1% **

    12  

     TYPE OF REPORTING PERSON*

     

     HC, IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    4


    CUSIP No. 84833T103    13G   

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Anson Advisors Inc.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Ontario, Canada

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     4,297,599

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     4,297,599

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,297,599

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.1% **

    12  

     TYPE OF REPORTING PERSON*

     

     FI, CO

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    5


    CUSIP No. 84833T103    13G   

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Amin Nathoo

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Canadian Citizen

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     4,297,599

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     4,297,599

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,297,599

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.1% **

    12  

     TYPE OF REPORTING PERSON*

     

     HC, IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    6


    CUSIP No. 84833T103    13G   

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Moez Kassam

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Canadian Citizen

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     4,297,599

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     4,297,599

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,297,599

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.1% **

    12  

     TYPE OF REPORTING PERSON*

     

     HC, IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    7


    SCHEDULE 13G

    This Schedule 13G (the “Schedule 13G”) is being filed on behalf of Anson Funds Management LP (d/b/a Anson Funds), a Texas limited partnership, Anson Management GP LLC, a Texas limited liability company, Mr. Tony Moore, the principal of Anson Funds Management LP and Anson Management GP LLC, Anson Advisors Inc., an Ontario, Canada corporation, Mr. Amin Nathoo, a director of Anson Advisors Inc., and Mr. Moez Kassam, a director of Anson Advisors Inc., relating to Common Stock, $0.001 par value (the “Common Stock”), of Spero Therapeutics, Inc., a Delaware corporation (the “Issuer”).

    This Schedule 13G relates to the Common Stock of the Issuer purchased by a private fund to which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors (the “Fund”). Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors to the Fund and may direct the vote and disposition of the 4,297,599 shares of Common Stock held by the Fund. As the general partner of Anson Funds Management LP, Anson Management GP LLC may direct the vote and disposition of the 4,297,599 shares of Common Stock held by the Fund. As the principal of Anson Fund Management LP and Anson Management GP LLC, Mr. Moore may direct the vote and disposition of the 4,297,599 shares of Common Stock held by the Fund. As directors of Anson Advisors Inc., Mr. Nathoo and Mr. Kassam may each direct the vote and disposition of the 4,297,599 shares of Common Stock held by the Fund.

     

    Item 1(a)

    Name of Issuer.

    Spero Therapeutics, Inc.

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices.

    675 Massachusetts Ave., 14th Floor

    Cambridge, MA, 02139

     

    Item 2(a)

    Name of Person Filing.

    Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo and Mr. Moez Kassam

     

    Item 2(b)

    Address of Principal Business Office, or, if none, Residence.

    For Anson Funds Management LP, Anson Management GP LLC and Mr. Moore:

    16000 Dallas Parkway, Suite 800

    Dallas, Texas 75248

    For Anson Advisors Inc., Mr. Nathoo and Mr. Kassam:

    181 Bay Street, Suite 4200

    Toronto, ON

    M5J 2T3

     

    8


    Item 2(c)

    Citizenship or Place of Organization.

    Anson Funds Management LP is a limited partnership organized under the laws of the State of Texas. Anson Management GP LLC is a limited liability company organized under the laws of the State of Texas. Mr. Moore is a United States citizen. Anson Advisors Inc. is a corporation organized under the laws of Ontario, Canada. Mr. Nathoo and Mr. Kassam are each Canadian citizens.

     

    Item 2(d)

    Title of Class of Securities.

    Common Stock, $0.001 par value

     

    Item 2(e)

    CUSIP Number.

    84833T103

     

    Item 3

    Reporting Person.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     

         (a)   ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
      (b)   ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c)   ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d)   ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
      (e)   ☒    An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).
      (f)   ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
      (g)   ☒    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
      (h)   ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
      (i)   ☐    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
      (j)   ☒    A non-U.S. institution that is the functional equivalent of any of the institutions listed in § 240.13d-1 (b)(1)(ii)(A) through (I), so long as the non-U.S. institution is subject to a regulatory scheme that is substantially comparable to the regulatory scheme applicable to the equivalent U.S. institution.
      (k)   ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    9


    Item 4

    Ownership.

     

      (a)

    Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 4,297,599 shares of Common Stock held by the Fund.

     

      (b)

    Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 8.1% of the outstanding shares of Common Stock. This percentage is determined by dividing 4,297,599 by 52,999,317 shares of Common Stock issued and outstanding, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2023.

     

      (c)

    Anson Funds Management LP and Anson Advisors Inc., as the co-investment advisors to the Fund, may direct the vote and disposition of the 4,297,599 shares of Common Stock held by the Fund. Anson Management GP LLC, as the general partner of Anson Funds Management LP, may direct the vote and disposition of the 4,297,599 shares of Common Stock held by the Fund. As the principal of Anson Funds Management LP and Anson Management GP LLC, Mr. Moore may direct the vote and disposition of the 4,297,599 shares of Common Stock held by the Fund. Mr. Nathoo and Mr. Kassam, each as a director of Anson Advisors Inc., may direct the vote and disposition of the 4,297,599 shares of Common Stock held by the Fund.

     

    Item 5

    Ownership of Five Percent or Less of a Class.

    Inapplicable.

     

    Item 6

    Ownership of More Than Five Percent on Behalf of Another Person.

    See description regarding the Fund in the introduction, which is incorporated by reference herein.

     

    Item 7

    Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.

    See description of control persons of Anson Funds Management LP and Anson Advisors Inc. in the introduction, which is incorporated by reference herein.

     

    Item 8

    Identification and Classification of Members of the Group.

    Inapplicable.

     

    Item 9

    Notice of Dissolution of Group.

    Inapplicable.

     

    Item 10

    Certification.

    By signing below each of the Reporting Persons certifies that, to the best of such person’s knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and were not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    10


    For Anson Advisors Inc.:

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to portfolio managers and exempt market dealers is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     

    Exhibits   

    Exhibit 99.1

       Joint Filing Agreement dated February 14, 2024, by and among Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam.

     

    11


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    ANSON FUNDS MANAGEMENT LP
    By: Anson Management GP LLC, its general partner
    By:   /s/ Tony Moore
      Tony Moore
      Manager
    ANSON MANAGEMENT GP LLC
    By:   /s/ Tony Moore
      Tony Moore
      Manager
    /s/ Tony Moore
    Tony Moore
    ANSON ADVISORS INC.
    By:   /s/ Amin Nathoo
      Amin Nathoo
      Director
    By:   /s/ Moez Kassam
      Moez Kassam
      Director
    /s/ Amin Nathoo
    Amin Nathoo
    /s/ Moez Kassam
    Moez Kassam

     

    12

    Get the next $SPRO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPRO

    DatePrice TargetRatingAnalyst
    12/20/2024$5.00Outperform → In-line
    Evercore ISI
    9/23/2022$2.00 → $8.00In-line → Outperform
    Evercore ISI
    10/1/2021Outperform → Perform
    Oppenheimer
    More analyst ratings

    $SPRO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Spero Therapeutics Inc.

    SCHEDULE 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

    8/14/25 9:48:21 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Spero Therapeutics Inc.

    S-8 - Spero Therapeutics, Inc. (0001701108) (Filer)

    8/12/25 5:12:49 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Spero Therapeutics Inc.

    10-Q - Spero Therapeutics, Inc. (0001701108) (Filer)

    8/12/25 4:31:07 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mahadevia Ankit was granted 20,000 shares, increasing direct ownership by 3% to 709,866 units (SEC Form 4)

    4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

    6/16/25 8:32:05 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Deshpande Milind was granted 20,000 shares, increasing direct ownership by 28% to 91,454 units (SEC Form 4)

    4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

    6/16/25 8:30:52 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jackson Scott Thomas was granted 20,000 shares, increasing direct ownership by 36% to 75,000 units (SEC Form 4)

    4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

    6/16/25 8:29:35 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

    PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero, along with its development partner, GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 Existing cash and earned and non-contingent development milestone payments from GSK provide anticipated runway to fund the Company's current operating expenses and capital expenditures into 2028 CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company foc

    8/12/25 4:01:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

    CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update. To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10200686, or click on this link and request a return call with passcode 0605709. The audio webcast can be

    8/5/25 4:05:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

    If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs2Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 that Spero's development partner, GSK, intends to submit CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) and GSK plc (LSE/NYSE:GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigation

    5/28/25 7:00:00 AM ET
    $GSK
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Spero Therapeutics downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Spero Therapeutics from Outperform to In-line and set a new price target of $5.00

    12/20/24 7:51:16 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Spero Therapeutics from In-line to Outperform and set a new price target of $8.00 from $2.00 previously

    9/23/22 7:52:34 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics downgraded by Oppenheimer

    Oppenheimer downgraded Spero Therapeutics from Outperform to Perform

    10/1/21 6:10:00 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Leadership Updates

    Live Leadership Updates

    View All

    Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

    CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since No

    4/28/25 4:01:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

    CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the appointment of Esther Rajavelu as Chief Financial Officer and Chief Business Officer. Ms. Rajavelu will succeed Stephen DiPalma, who has served as the company's Interim CFO since August 1, 2023. "We are thrilled to welcome Esther to the executive leadership team as our new CFO and CBO. Esther brings a proven track record in corporate finance, from both indus

    11/1/23 8:05:00 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

    BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition

    9/12/23 8:00:00 AM ET
    $PTCT
    $SPRO
    $TCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SPRO
    Financials

    Live finance-specific insights

    View All

    Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

    PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero, along with its development partner, GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 Existing cash and earned and non-contingent development milestone payments from GSK provide anticipated runway to fund the Company's current operating expenses and capital expenditures into 2028 CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company foc

    8/12/25 4:01:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

    CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update. To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10200686, or click on this link and request a return call with passcode 0605709. The audio webcast can be

    8/5/25 4:05:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

    CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infect

    5/5/25 8:00:00 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Spero Therapeutics Inc.

    SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

    11/14/24 5:37:55 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Spero Therapeutics Inc.

    SC 13G - Spero Therapeutics, Inc. (0001701108) (Subject)

    2/14/24 4:25:21 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Spero Therapeutics Inc. (Amendment)

    SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

    2/14/23 11:47:54 AM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care